Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.
external beam radiation therapy
immune checkpoint inhibitors
immunogenic cell death
inflammation
nivolumab
pembrolizumab
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
04
07
2023
revised:
20
07
2023
accepted:
24
07
2023
medline:
23
10
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple cancer types. However, only a fraction of patients with cancer responds to ICIs employed as stand-alone therapeutics, calling for the development of safe and effective combinatorial regimens to extend the benefits of ICIs to a larger patient population. In addition to exhibiting a good safety and efficacy profile, targeted radionuclide therapy (TRT) with radiopharmaceuticals that specifically accumulate in the tumor microenvironment has been associated with promising immunostimulatory effects that (at least in preclinical cancer models) provide a robust platform for the development of TRT/ICI combinations. We discuss preclinical and clinical findings suggesting that TRT stands out as a promising partner for the development of safe and efficient combinatorial regimens involving ICIs.
Identifiants
pubmed: 37612188
pii: S2405-8033(23)00141-3
doi: 10.1016/j.trecan.2023.07.014
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Radiopharmaceuticals
0
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Review
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
968-981Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.P.P. holds research contracts with Orano, Precirix, NH TherAguix, AKEN Medical, and Institut Roche. L.G. holds research contracts with Lytix Biopharma, Promontory, and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. The other authors declare no conflicts of interests.